Ipramid Respirator Solution Solution

Asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema.

Inhalation Asthma; Chronic obstructive pulmonary disease Adult: As Inhaler: Adults: 1-2 puffs (20 mg/puff) 3-4 times daily. Single doses of up to 80 mcg may be required in some patients. As nebulized soln 250-500 mcg 3-4 times daily.

Inhalation Asthma; Chronic obstructive pulmonary disease Child: As metered-dose aerosol: <6 yr 20 mcg tid; 6-12 yr 20-40 mcg tid. As soln for nebulisation: <6 yr For acute asthma: 125-250 mcg, given no more often than 6 hrly up to a total dose of 1 mg. 6-12 yr For acute and chronic asthma: 250 mcg, repeated as necessary up to a total dose of 1 mg.

Ipratropium Bromide solution should not be taken by patients with known hypersensitivity to atropine or its derivatives or to any other component of the product.

Bladder neck obstruction, narrow-angle glaucoma or patients susceptible to glaucoma, prostatic hyperplasia. Protect patient's eyes from nebulised drug. Renal and hepatic impairment. Pregnancy, lactation, children, elderly.

B Pregnancy category: B Lactation: Unknown whether drug is excreted in breast milk

Increased toxicity with other anticholinergic drugs.

Dry mouth, urinary retention, buccal ulceration, paralytic ileus, headache, nausea, constipation, paradoxical bronchospasm, immediate hypersensitivity reactions (urticaria, angioedema), acute angle-closure glaucoma. Potentially Fatal: Anaphylactic reactions, atrial fibrillation, supraventricular tachycardia.

Ipratropium bromide blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation.

Ipramid Respirator Solution 250mcg/ml Solution manufactured by Beximco Pharmaceuticals Ltd.. Its generic name is Ipratropium Bromide.